According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...
The lung cancer survival rate improved 26 percent in the last five years, according to the "State of Lung Cancer" report ...
The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...
The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...
This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.
Rhode Island ranked second for its lung cancer survival rate, with more than 35% living five years post diagnosis. The state ...
Lung cancer is the third most common cancer and the leading cause of cancer-related deaths in the U.S., and according to the ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
Dr. Heba Ismail at Sutter Health’s California Pacific Medical Center has dedicated her career to the early detection and ...
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...